KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) EPS (Weighted Average and Diluted) (2017 - 2025)

Cardlytics (CDLX) has disclosed EPS (Weighted Average and Diluted) for 8 consecutive years, with -$0.15 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 40.0% year-over-year to -$0.15, compared with a TTM value of -$1.95 through Dec 2025, up 48.28%, and an annual FY2025 reading of -$1.95, up 50.13% over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.15 for Q4 2025 at Cardlytics, up from -$1.36 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.91 in Q1 2022 and bottomed at -$11.32 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$1.38, with a median of -$0.56 recorded in 2021.
  • The sharpest move saw EPS (Weighted Average and Diluted) skyrocketed 207.06% in 2022, then tumbled 500.0% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.56 in 2021, then tumbled by 1921.43% to -$11.32 in 2022, then surged by 75.8% to -$2.74 in 2023, then skyrocketed by 90.88% to -$0.25 in 2024, then soared by 40.0% to -$0.15 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for CDLX at -$0.15 in Q4 2025, -$1.36 in Q3 2025, and -$0.18 in Q2 2025.